Overview

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Status:
Not yet recruiting
Trial end date:
2031-05-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Bortezomib
Dexamethasone
Pomalidomide